A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Last trade$182.47
Day change-$1.55 (-0.84%)
Day range$181.15 – $183.77
Volume1,482,208
Market cap$285.40B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$285.4B
Price / earnings
128.5×
Price / book
21.09×
Price / sales
11.86×
EV / sales
12.49×
EV / EBITDA
56.42×
Profitability
Earnings per share
$1.43
Return on assets
3.45%
Return on equity
16.42%
Dividend yield
1.24%
Liquidity and leverage
Debt / equity
1.4×
Current ratio
0.93×
Quick ratio
0.76×
Cash ratio
0.27×
Cash flow
Price / cash flow
77.34×
Price / free cash flow
125.45×
Free cash flow
$2.28B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AZN, quarterly periods
Line item
Q2 FY2016 Jun 30, 2016
Q1 FY2016 Mar 31, 2016
Q4 FY2015 Dec 31, 2015
Q3 FY2015 Sep 30, 2015
Q2 FY2015 Jun 30, 2015
Q1 FY2015 Mar 31, 2015
Q4 FY2014 Dec 31, 2014
Q3 FY2014 Sep 30, 2014
Revenue
$5.6B
$6.12B
$6.4B
$5.95B
$6.31B
$6.06B
$6.72B
$6.61B
Cost of revenue
$1.15B
$1.08B
$1.37B
$1.12B
$1.15B
$1.35B
$1.76B
$1.5B
Gross profit
$4.45B
$5.04B
$5.03B
$4.83B
$5.16B
$4.71B
$4.96B
$5.11B
Selling, general and administrative
$3.05B
$2.57B
$2.67B
$2.68B
$2.97B
$2.8B
$4.08B
$3.13B
Research and development
$1.47B
$1.48B
$1.75B
$1.43B
$1.47B
$1.36B
$1.5B
$1.55B
Total operating expenses
$4.15B
$4B
$3.94B
$3.66B
$4.23B
$3.78B
$5.31B
$4.57B
Operating income
$303M
$1.04B
$1.09B
$1.17B
$923M
$933M
-$349M
$541M
Interest expense
-$342M
-$325M
-$292M
-$246M
-$276M
-$261M
-$260M
-$236M
Income before taxes
-$30M
$723M
$802M
$931M
$658M
$678M
-$580M
$322M
Income taxes
$1M
$98M
-$6M
$161M
-$38M
$126M
-$259M
$69M
Net income
-$31M
$625M
$808M
$770M
$696M
$552M
-$321M
$253M
Net income attributable to common shareholders
-$3M
$646M
$808M
$770M
$697M
$550M
-$321M
$254M
EBITDA
$890M
$1.61B
$1.09B
$1.74B
$1.64B
$1.78B
-$349M
$1.39B
Basic earnings per share
$0.00
$0.51
$0.63
$0.61
$0.55
$0.44
-$0.25
$0.20
Diluted earnings per share
$0.00
$0.51
$0.64
$0.60
$0.55
$0.44
-$0.25
$0.20
Recent news
Company coverage with links to the original publishers.
AstraZeneca reported Q3 2026 revenues of $16.21 billion (up 7% YoY) and core EPS of $2.79, beating consensus estimates. Strong oncology sales growth (16% to $21.9B) and new drug launches support the company's $80 billion 2030 revenue target. However, generic erosion of mature drugs, recent pipeline failures, and China market uncertainties create headwinds. The company maintains mid-to-high single-digit revenue growth guidance for 2026.
The systemic sclerosis market is valued at USD 1.9 billion in 2025 and is projected to grow at a 3% CAGR through 2036. Growth is driven by increasing disease awareness, diagnostic advancements, and an expanding pipeline of emerging therapies including anifrolumab, belimumab, efzofitimod, and nemolizumab. The U.S. accounts for 55% of the market, with approximately 232K diagnosed cases across the 7MM in 2025.
AstraZeneca received FDA and EU regulatory approvals for Klygefa (gefurulimab), a complement C5 inhibitor for treating adults with AChR-positive generalized myasthenia gravis. The once-weekly, self-administered subcutaneous therapy showed significant improvements in daily activities versus placebo in Phase III trials. While the convenient dosing offers differentiation from AstraZeneca's existing IV therapies (Soliris and Ultomiris), Klygefa faces cannibalization risks and competition from other complement C5 inhibitors and alternative mechanism drugs.
Summit Therapeutics' shares plunged over 20% after receiving an FDA Complete Response Letter for its cancer drug ivonescimab, failing to meet overall survival statistical requirements in the HARMONi trial. However, analysts view the setback as limited since it affects only second-line treatment, with the drug's main blockbuster potential in first-line settings. Summit has 17 ongoing late-stage trials, strong financial backing from AstraZeneca, and $630 million in cash reserves to continue development.
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Aug 7, 2026
£0.795
Sep 8, 2026
recurring
Feb 20, 2026
£1.595
Mar 23, 2026
recurring
Aug 8, 2025
$1.03
Sep 8, 2025
recurring
Feb 21, 2025
$2.10
Mar 24, 2025
recurring
Aug 9, 2024
$1.00
Sep 9, 2024
recurring
Stock splits
Historical share-structure events and their execution dates.